Another report demonstrated a significant decrease in the percentage of CD3− CD16+ CD56+bright and CD3− CD16+ CD56+dim NK cell subsets after exposure of PBLs to ASCs either from normal donors or patients with BC (pathological stage II/III). This evidence concerns the gene NCAM1 and breast cancer.